The FDA has approved Novo Nordisk’s Ozempic—once-weekly semaglutide—for an expanded indication of CV risk reduction in people with type 2 diabetes and established heart disease.
A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.
Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.
U.K.-based drug giant AstraZeneca announced Jan. 13 it would be halting its Phase III trial of Epanova, a medication comprised of omega-3 carboxylic acids, early due to disappointing data.
Research led by a team at the University of Kentucky and funded by the American Heart Association and National Institutes of Health has uncovered a new biomarker for cardiovascular disease: an apolipoprotein/antibody combo.
The American Heart Association on Dec. 13 announced that it would be awarding more than $14 million in research grants to advance its new Strategically Focused Research Network on Cardiometabolic Health and Type 2 Diabetes.
Atrial fibrillation patients who are obese are less likely to respond to sodium channel blockers than their normal-weight peers, according to a new study.
A study published in JACC suggests that, when combined with high-intensity statin therapy, evolocumab can be an effective tool for lowering LDL-cholesterol in patients who have experienced an acute coronary syndrome.
